منابع مشابه
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin, M.D., Ph.D., Richard C. Becker, M.D., Andrzej Budaj, M.D., Ph.D., Christopher P. Cannon, M.D., Håkan Emanuelsson, M.D., Ph.D., Claes Held, M.D., Ph.D., Jay Horrow, M.D., Steen Husted, M.D., D.Sc., Stefan James, M.D., Ph.D., Hugo Katus, M.D., Kenneth W. Mahaffey, M.D., Benjamin M. Scirica, M.D., M.P.H., Allan Skene, Ph.D., Philippe Gabriel Steg, M.D., Robert F. Storey, M.D., D.M....
متن کاملRole of ticagrelor in clopidogrel nonresponders: resistance is futile?
Dual antiplatelet therapy with aspirin and a thienopyridine drug that blocks the platelet adenosine diphosphate receptor P2Y12 is the cornerstone of management in patients presenting with acute coronary syndrome (ACS). Clopidogrel is the most widely used thienopyridine, with evidence of benefit in non–ST-elevation myocardial infarction (MI),1 percutaneous coronary intervention (PCI),2 and ST-el...
متن کاملSwitching from ticagrelor to clopidogrel: New answers and further questions.
Thromb Haemost 2017; 117: 303–310 Switching antiplatelet therapies is a common occurrence in clinical practice (1). The current availability of different oral P2Y12 receptor antagonists allows for multiple treatment options and has raised questions on the optimal approach if switching among these therapies is needed or desired. Despite the evidence for sustained efficacy and safety of ticagrelo...
متن کاملReduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
BACKGROUND We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (e.g., cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thro...
متن کاملCost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada
BACKGROUND Ticagrelor demonstrated a significant reduction in major cardiac events in patients with acute coronary syndrome (ACS) compared with clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. The objective of this study was to assess the cost-effectiveness of ticagrelor compared with clopidogrel in ACS patients from the perspective of the Canadian publicly funded heal...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: MMW - Fortschritte der Medizin
سال: 2012
ISSN: 1438-3276
DOI: 10.1007/s15006-012-1224-7